Aurinia Pharmaceuticals (NASDAQ:AUPH) Releases Earnings Results, Beats Expectations By $0.07 EPS

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) posted its quarterly earnings data on Tuesday. The biotechnology company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.07, Zacks reports. Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. The company had revenue of $73.47 million during the quarter, compared to analysts’ expectations of $67.70 million. Aurinia Pharmaceuticals updated its FY 2025 guidance to EPS.

Aurinia Pharmaceuticals Stock Up 1.3%

NASDAQ:AUPH traded up $0.18 during trading hours on Wednesday, reaching $14.45. The company had a trading volume of 3,019,188 shares, compared to its average volume of 1,650,046. The company has a quick ratio of 4.63, a current ratio of 5.23 and a debt-to-equity ratio of 0.18. The firm has a market cap of $1.90 billion, a price-to-earnings ratio of 33.61 and a beta of 1.25. The business’s 50-day simple moving average is $12.14 and its two-hundred day simple moving average is $10.06. Aurinia Pharmaceuticals has a twelve month low of $6.55 and a twelve month high of $16.20.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets increased its position in Aurinia Pharmaceuticals by 32.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 13,034 shares of the biotechnology company’s stock valued at $110,000 after buying an additional 3,191 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Aurinia Pharmaceuticals by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,811 shares of the biotechnology company’s stock worth $642,000 after acquiring an additional 3,497 shares in the last quarter. Creative Planning grew its stake in Aurinia Pharmaceuticals by 21.0% in the second quarter. Creative Planning now owns 20,699 shares of the biotechnology company’s stock valued at $175,000 after acquiring an additional 3,594 shares during the period. Hudson Bay Capital Management LP grew its stake in Aurinia Pharmaceuticals by 4.0% in the second quarter. Hudson Bay Capital Management LP now owns 104,000 shares of the biotechnology company’s stock valued at $881,000 after acquiring an additional 4,000 shares during the period. Finally, Russell Investments Group Ltd. increased its holdings in shares of Aurinia Pharmaceuticals by 6.0% during the second quarter. Russell Investments Group Ltd. now owns 82,509 shares of the biotechnology company’s stock valued at $699,000 after acquiring an additional 4,666 shares in the last quarter. Institutional investors own 36.83% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on AUPH. Royal Bank Of Canada restated a “sector perform” rating and issued a $15.00 target price (up previously from $9.00) on shares of Aurinia Pharmaceuticals in a report on Wednesday. HC Wainwright reissued a “buy” rating and issued a $17.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 30th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $16.00.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.